(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.9%.
An2 Therapeutics's earnings in 2025 is -$37,380,000.On average, 1 Wall Street analyst forecast ANTX's earnings for 2025 to be -$28,145,950, with the lowest ANTX earnings forecast at -$28,145,950, and the highest ANTX earnings forecast at -$28,145,950. On average, 1 Wall Street analyst forecast ANTX's earnings for 2026 to be -$26,233,118, with the lowest ANTX earnings forecast at -$26,233,118, and the highest ANTX earnings forecast at -$26,233,118.
In 2027, ANTX is forecast to generate -$22,953,979 in earnings, with the lowest earnings forecast at -$22,953,979 and the highest earnings forecast at -$22,953,979.